MAG expression promoters
AssigneeMitsubishi Pharma Corporation
InventorsMasakazu Kawasaki, Nobuharu Gotoh, Yoshiharu Hayashi, Kazuyuki Kawasaki
Life of this patent
Estimating the term…
Loading patent…
AssigneeMitsubishi Pharma Corporation
InventorsMasakazu Kawasaki, Nobuharu Gotoh, Yoshiharu Hayashi, Kazuyuki Kawasaki
Estimating the term…
The MAG expression promoter of the present invention contains a compound of the formula (I) wherein each symbol is as defined in the specification, an optically active form thereof or a pharmaceutically acceptable salt thereof. As a compound of the formula (1), 4-[α-hydroxy-5-(1-imidazolyl)-2-methylbenzyl]-3,5-dimethylbenzoic acid is exemplified. The MAG expression promoter of the present invention is useful as an agent for the prophylaxis and/or treatment of a disease of mammals inclusive of humans, which mainly presents hypomyelination, further, dysmyelination or demyelination.
A MAG method of promoting expression of MAG comprising administering a compound of the formula (I)
2-9. (canceled)
A method for promoting a mvelination of axon, which method comprises administering a compound of the formula (I)
A method for promoting a mvelination. of axon, which method comprises administering 4-[α-hydroxy-5-(1-imidazolyl)-2-methylbenzyl]-3,5-dimethylbenzoic acid, an optically active form thereof or a pharmaceutically acceptable salt thereof to a mammal.
A method for promoting a myclination of axon, which method comprises administering a compound of the formula (I)
A method for promoting a myelination of axon, which method comprises administering 4-[α-hydroxy-5-(1-imidazolyl)-2-methylbenzyl]-3,5-dimethylbenzoic acid, an optically active form thereof or a pharmaceutically acceptable salt thereof to a mammal.
16-33. (canceled)
Dependencies are inferred from the claim text.